Conmed (CNMD) Tops Q4 EPS by 1c; Guides
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
Leerink Partners Remains Bullish as Conmed's (CNMD) Growth Acceleration Shows Evolving Turnaround
January 28, 2016 10:10 AM ESTLeerink Partners reiterated an Outperform rating on CONMED (NASDAQ: CNMD), and cut the price target to $50.00 (from $51.00), following the company's 4Q report. Results were marked by solid growth acceleration in ortho and in Leerink's view, the Surgiquest acquisition should be an important catalyst for the... More
